Rhumbline Advisers Fulcrum Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 88,993 shares of FULC stock, worth $267,868. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,993
Previous 88,607
0.44%
Holding current value
$267,868
Previous $416,000
35.82%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding FULC
# of Institutions
130Shares Held
51.4MCall Options Held
1.04MPut Options Held
32.6K-
Ra Capital Management, L.P. Boston, MA10.2MShares$30.8 Million0.78% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$15.8 Million4.03% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$14.4 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$14.4 Million1.13% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.34MShares$10 Million0.65% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $157M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...